Compare Davita Inc (DVA) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Monster Beverage Corp — how do they compare? Davita Inc trades at $179.07 (market cap $11.29B), while Monster Beverage Corp trades at $43.66 (market cap $85.51B). The key difference: Monster Beverage Corp is far larger — about 7.6× Davita Inc's market cap, and Davita Inc is more actively traded (582,204 versus 8,569,709). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Monster Beverage Corp for 72 Days on average.
| DVA | MNST | |
|---|---|---|
Market Cap | $11.29B | $85.51B |
Volume | 582,204 | 8,569,709 |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $49.97 |
52-Week Low | $103.87 | $33.16 |
Typical Hold Time | 113 Days | 72 Days |
Enterprise Value | $24.01B | $83.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.02, up 1.26% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 6.05% net margins and 635% ROE. Recent partnerships with Humana expand value-based kidney care services, while institutional investors like BlackRock added significant positions. Revenue growth remains steady at $13.6B annually with improving profitability trends.
DVA presents a mixed outlook with strong operational performance offset by technical weakness. The 43% upside to consensus price target of $235.67 offers potential, but high debt levels and regulatory risks require monitoring. Recent earnings momentum and expanding Medicare partnerships support long-term growth, though current technical indicators suggest near-term consolidation.
Monster Beverage (MNST) trades at $43.58, up 1.63% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust profitability with a net margin of 23.08% and zero long-term debt. Recent news highlights international sales growth of 35% in Q2 and a 1:2 stock split effective August 2026.
Outlook remains positive with a consensus price target of $98.22, implying significant upside, supported by international expansion and a debt-free balance sheet. Risks include competitive pressures, regulatory challenges in markets like India, and rich valuation multiples such as a P/E of 40.42. Analyst consensus is bullish with 52% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
